General
Novo Nordisk names new CEO amid share price slump and concerns over Wegovy, Ozempic sales
Danish pharmaceutical giant Novo Nordisk, known for its weight-loss drugs Wegovy and Ozempic, has named Maziar Mike Doustdar as its new chief executive, relying on an experienced company insider to make up ground lost to market rivals.
Mr Doustdar’s appointment came on Tuesday after the abrupt…
Continue Reading
-
Noosa News23 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News24 hours agoMotorcyclist dies in crash with truck
-
Noosa News22 hours agoAustralia Post reintroduces weekend deliveries for Christmas parcel rush
-
Business21 hours agoWhy this investing expert is calling time on NAB shares